Acetohydroxyacid synthase (AHAS) is the first enzyme in the branched-chain amino acid biosynthesis pathway in bacteria. Bioinformatics analysis revealed that the Mycobacterium tuberculosis genome contains four genes (ilvB1, ilvB2, ilvG and ilvX) coding for the large catalytic subunit of AHAS, whereas only one gene (ilvN or ilvH) coding for the smaller regulatory subunit of this enzyme was found. In order to understand the physiological role of AHAS in survival of the organism in vitro and in vivo, we inactivated the ilvB1 gene of M. tuberculosis. The mutant strain was found to be auxotrophic for all of the three branched-chain amino acids (isoleucine, leucine and valine), when grown with either C 6 or C 2 carbon sources, suggesting that the ilvB1 gene product is the major AHAS in M. tuberculosis. Depletion of these branched chain amino acids in the medium led to loss of viability of the DilvB1 strain in vitro, resulting in a 4-log reduction in colony-forming units after 10 days. Survival kinetics of the mutant strain cultured in macrophages maintained with sub-optimal concentrations of the branched-chain amino acids did not show any loss of viability, indicating either that the intracellular environment was rich in these amino acids or that the other AHAS catalytic subunits were functional under these conditions. Furthermore, the growth kinetics of the DilvB1 strain in mice indicated that although this mutant strain showed defective growth in vivo, it could persist in the infected mice for a long time, and therefore could be a potential vaccine candidate.
INTRODUCTION
Mycobacterium tuberculosis, the causative agent of tuberculosis, infects approximately one-third of the world population and is responsible for a significant number of deaths (Hoft, 2008) . Even though the disease can be controlled with a combination of drugs, the long duration of treatment results in non-compliance, which leads to relapse of the disease and evolution of drug resistance in the organism. The presence of drug-resistant bacteria poses a serious challenge to the treatment of tuberculosis, since a significant number of bacteria are resistant to single and multiple drugs all over the world (Chan & Iseman, 2008) . The availability of good genetic tools and the publication of the genome sequence of M. tuberculosis (Cole et al., 1998) have led to rapid advances in understanding the biology of this important pathogen. Although a number of new inhibitors of M. tuberculosis have been reported, none has been advanced enough to be used clinically (Rivers & Mancera, 2008) . Similarly, efforts to design new vaccines have also met with limited success (Hoft, 2008) . Thus, identification and validation of new M. tuberculosis proteins as drug or vaccine candidates will help with the development of novel therapeutic approaches to control tuberculosis.
Acetohydroxyacid synthase (AHAS), also known as acetolactate synthase (ALS), is the key enzyme involved in biosynthesis of branched-chain amino acids (BCAA) in bacteria. AHAS catalyses the conversion of two pyruvate molecules into acetolactate, and is also involved in condensing pyruvate and 2-ketobutyrate to form 2-aceto-2-hydroxybutyrate. The absence of this enzyme from higher eukaryotes makes it an attractive target for development of anti-mycobacterials. In fact, inhibitors of AHAS, sulfonylureas, are a well-known group of herbicides that are also capable of inhibiting the growth of a number of bacteria, including mycobacteria (LaRossa & Schloss, 1984; Grandoni et al., 1998; Zohar et al., 2003) . AHAS has been well characterized in enterobacteria, and three isozymes of AHAS (type I IlvBN, type II IlvGM and type III IlvIH) have been reported from Escherichia coli and Salmonella typhimurium (Guardiola et al., 1974; Shaw et al., 1980) . The three species of AHAS differ from each other in certain biochemical characteristics, such as sensitivity to valine and inhibition by sulfonylureas (Barak et al., 1987) . In terms of their role in different physiological conditions, it has been postulated that the three isoforms of AHAS are critical for growth on different carbon sources, with AHAS I playing a major role during growth on acetate or palmitate, while AHAS II is required for growth in the presence of glucose (Barak et al., 1987; Dailey et al., 1987) . It has been proposed that unlike Gram-negative bacteria, the Gram-positive bacteria possess a single species of AHAS. The biochemical characterization of recombinant AHAS from Bacillus stearothermophilus, which has been designated IlvBN, revealed that it is a functional equivalent of the type III AHAS (IlvIH) of enterobacteria (Porat et al., 2004) . Similarly, Corynebacterium glutamicum was shown to possess a single species of AHAS (IlvBN), which is responsible for the synthesis of BCAA (Keilhauer et al., 1993) . Biochemical characterization of a recombinant AHAS (IlvBN) from two mycobacterial species, Mycobacterium avium and M. tuberculosis, has been reported (Zohar et al., 2003; Choi et al., 2005) . Both of these enzymes could be inhibited by sulfonylureas and were shown to be sensitive to inhibition by valine, to varying extents.
Auxotrophic mutants of a number of bacteria with varied nutritional requirements, such as aromatic amino acids, co-factors, purines and pyrimidines, have been shown to be attenuated for virulence in mice. This suggests that the in vivo environment does not provide sufficient amounts of the various amino acids and co-factors required for growth (Hoiseth & Stocker, 1981; Alexander et al., 1993; Hondalus et al., 2000; Atkins et al., 2002) . As these mutants can persist in animals for long periods of time without causing disease, a number of them have been evaluated as vaccine candidates. In particular, an AHAS mutant of Burkholderia pseudomallei, which requires isoleucine, leucine and valine (ILV) for growth, was found to be attenuated for virulence in mice. Animals vaccinated with the mutant strain were protected against challenge by virulent bacteria (Atkins et al., 2002) . As the current vaccine, M. bovis BCG, does not offer good protection against tuberculosis, a number of approaches to generate better vaccines have been tried (Martin, 2006) . Amongst them, use of auxotrophic mutants as vaccine candidates has been attempted by a number of investigators with varying degrees of success (Jackson et al., 1999; Hondalus et al., 2000; Smith et al., 2001; Sambandamurthy & Jacobs, 2005) . A purC mutant of M. tuberculosis was shown to offer protection against virulent M. tuberculosis in a guinea pig model (Jackson et al., 1999) . Mutants exhibiting double auxotrophy (lysine and pantothenate or leucine and pantothenate) have been found to persist in animals for long periods of time, and were effective in reducing organ pathology and bacterial loads when mice and guinea pigs were challenged with virulent M. tuberculosis (Sambandamurthy & Jacobs, 2005) . The availability of M. tuberculosis mutants requiring BCAA for growth would provide an opportunity for assessing their protective ability against tuberculosis.
The absence of AHAS enzymes from humans, and their specific inhibition by sulfonylureas, have led to the idea of using AHAS as a possible antibacterial drug target. Although wild-type S. typhimurium, carrying genes coding for all three species of AHAS, were found to be resistant to sulfonylureas, mutants lacking IlvBN were sensitive to these herbicides, pointing to the possibility of using sulfonylureas for therapeutic purposes in bacteria lacking homologues of IlvBN (LaRossa & Schloss, 1984; LaRossa & Smulski, 1984) . It has also been reported that the growth of Brucella abortus inside macrophages could be inhibited by sulfonylureas, raising the possibility of using AHAS as a drug target for intracellular pathogens (Boigegrain et al., 2005) . Although sulfonylureas have been shown to inhibit the growth of M. tuberculosis (Grandoni et al., 1998) , the redundancy of genes coding for the larger subunit of AHAS in this organism makes it difficult to conclude whether the effects of sulfonylureas result from inhibition of single or multiple isozymes of AHAS. In order to understand the role of AHAS in the growth and survival of mycobacteria in vitro and in vivo, and to validate AHAS as a drug target or vaccine candidate, we inactivated the ilvB gene of M. tuberculosis and studied the mutant phenotype in vitro, and in macrophages and mice. Our data suggest that IlvB of M. tuberculosis is the major AHAS required for BCAA synthesis. The survival kinetics of the mutant in mice suggests that the DilvB1 strain of M. tuberculosis might be a suitable vaccine candidate.
METHODS
Bacterial strains. The strains used in this study are listed in Table 1 .
Materials. Amino acids (isoleucine, leucine and valine) and pantothenic acid were obtained from Sigma. Hygromycin B was purchased from Roche.
Bioinformatics analysis. AHAS large subunits from E. coli K-12 and M. tuberculosis were collated from Colibri (http://genolist.pasteur.fr/ Colibri/) and TubercuList (http://genolist.pasteur.fr/TubercuList/), respectively. The respective amino acid sequences of E. coli and M. tuberculosis proteins were retrieved from Swiss-Prot and TREMBL, aligned using PILEUP, and the multiple sequence alignment was generated using Jalview. Sequences selected for alignment were as follows: E. coli IlvB (b3671), IlvG (b3767) and IlvI (b0077); M. tuberculosis IlvB1 (Rv3003c), IlvB2 (Rv3470c), IlvG (Rv1820) and IlvX IP: 54.70.40.11
On: Sat, 22 Dec 2018 10:40:19 (Rv3509c). The identity and similarity matrix of AHAS large subunit protein sequences from E. coli and M. tuberculosis was generated using MatGAT1.8 (Matrix Global Alignment Tool).
M. tuberculosis culture conditions. M. tuberculosis H37Rv cultures were routinely grown in 7H9 or 7H11 medium (Difco) containing albumin dextrose complex (ADC). Isoleucine, leucine and valine (100 mg ml 21 each), pantothenic acid (50 mg ml 21 ), hygromycin (50 mg ml 21 ) or kanamycin (10 mg ml 21 ) were added to 7H9+ADC culture medium when required.
DNA amplification by PCR. Screening of single-crossover (SCO) and double-crossover (DCO) recombinants in M. tuberculosis was done by PCR using Taq DNA polymerase. Single colonies were picked from plates, resuspended in 50 ml TE (10 mM Tris, 1 mM EDTA) and boiled for 10 min. Five microlitres of this cell lysate was used for PCR in a 25 ml volume. The denaturation and extension reactions were performed at 94 uC and 72 uC respectively. The annealing temperature and extension time for each PCR was based on the Tm of the primer pair and length of the PCR product. The sequences of the primers used in this study are given in Table 2 .
Plasmid constructs. The plasmids used in this study are described in Table 1 . The construction of the knockout construct was outsourced to Bangalore Genei. The recombination substrate for creating a deletion in the ilvB1 gene of M. tuberculosis consisted of the mutant gene with flanking sequences, cloned into a suicide vector, pGOAL19. The 205 bp deletion in the ilvB1 gene (base pairs 258-463) was generated by overlapping PCR in such a way that the deleted region was flanked by 817 bp on the 59 side and 864 bp on the 39 side of the deletion. The 1693 bp PCR-amplified DNA fragment was first cloned into a TA cloning vector (pDK101) and was subsequently moved into the ScaI site of pGOAL19, to generate the knockout construct pAZI0235. In order to convert pMV261 (Stover et al., 1991) into an integrating vector, a MluI-XbaI fragment from pYUB178 (Pascopella et al., 1994) containing att and int sites was used to replace a MluI-XbaI fragment (encompassing oriM) from pMV261. The resulting plasmid was designated pAZI272. To make the complementation construct, the ilvB1 gene was amplified from M. tuberculosis genomic DNA and cloned into the EcoRI-HindIII sites of the mycobacterial expression vector pAZI272, to produce pAZI0259. The sequence of the cloned fragments was confirmed by DNA sequencing. The plasmids were electroporated into M. tuberculosis as described by Wards & Collins (1996) .
Southern blotting. Genomic DNA from the wild-type M. tuberculosis and the ilvB1 mutant was digested with NruI and electrophoresed on a 0.8 % agarose gel. A probe was generated by PCR amplification of an internal fragment of the ilvB1 gene, using primers 356 and 486, corresponding to the upstream and downstream regions of the deletion. The PCR fragment was fluorescein-labelled by random prime labelling (Roche). Transfer, hybridization and washing were performed following the manufacturer's protocol (GE Healthcare). The bound probe was detected by horseradishperoxidase-conjugated anti-fluorescein antibodies (1 : 2000 dilution) using chemiluminiscence.
Growth and death kinetics in vitro. Wild-type and DilvB1 M. tuberculosis cultures were grown in 7H9 in the presence of amino acids, when required, to OD 600 1.0. For growth studies, the cultures were washed and resuspended in plain 7H9 broth. These cultures were then divided and grown with increasing concentrations of ILV or different combinations of Ile, Leu and Val. To study the survival kinetics of the DilvB1 mutant in the absence of ILV, a culture grown in 7H9 containing ILV was washed with plain 7H9 and resuspended in fresh 7H9, with and without amino acids. The cultures were incubated at 37 uC for 4 weeks, and viability of the cultures was monitored at regular intervals by plating various dilutions onto 7H9 plates containing ILV (each 100 mg ml 21 ) and 50 mg pantothenic acid ml 21 . C.f.u. were counted after 1 month.
Growth of M. tuberculosis H37Rv and the DilvB1 mutant in macrophages. Intracellular infection and survival kinetics of mycobacterial strains were investigated in gamma-interferon-activated primary cultures of bone-marrow-derived macrophages (BMDM), in a 24-well plate format, as described by Muñoz-Elías & McKinney (2005) . Briefly, bone marrow cells were flushed from mouse femurs and cultured in complete RPMI 1640 medium (Gibco Laboratories) with 20 % L929 conditioned medium, for 5 days. The macrophage monolayers were activated by addition of 25 ng ml 21 recombinant IFN-gamma (Sigma) for 48 h. Activated and washed 
RESULTS

Bioinformatics analysis of AHAS genes in M. tuberculosis
In the KEGG and TubercuList genome databases, the following M. tuberculosis genes have been suggested to code for large subunits of AHAS: ilvB1, ilvB2, ilvG and ilvX.
Only one gene, ilvH, which was also designated ilvN in an earlier study (Choi et al., 2005) , has been annotated as the gene coding for the smaller regulatory subunit of AHAS. The genomic organization of the AHAS-coding genes in M. tuberculosis is shown in Fig. 1 . The distribution of genes coding for large subunits of AHAS into different operons probably allows differential transcriptional regulation of these genes under varied environmental conditions. The organization of ilvB1 and ilvH into an operon, ilvB1HC, is reminiscent of the transcriptional coupling of ilvBNC, in which ilvB, ilvN and ilvC code for large and small subunits of type I AHAS and ketol-acid reductoisomerase, respectively, in a number of Gram-positive bacteria ( Supplementary Fig.  S1) . A number of genes not involved in BCAA synthesis are also present in the operons of M. tuberculosis, as shown in Fig. 1 . These include a pre-protein translocase subunit (SecA2) and hypothetical proteins (Rv3471c and Rv3510c). The functional significance of these unrelated genes in the ilv operons is not understood. In terms of similarity with E. coli proteins, IlvB1 of M. tuberculosis shows greatest homology to IlvG (type II) and IlvI (type III), followed by IlvB (type I) of E. coli (Table 3) . Analysis of regions involved in TPP and FAD binding, and active-site residues of IlvBI, also showed maximum similarity with IlvG and IlvI of E. coli ( Supplementary Fig. S2 ). The other large subunits of M. tuberculosis AHAS (IlvB2, IlvG and IlvX) showed much less homology (approx 21-26 % identity) to the large subunits of E. coli. Homology analysis of the smaller regulatory protein (IlvH or IlvN) showed that it had greatest homology to IlvH (smaller subunit of type III) of E. coli. Based upon the homology analysis it is tempting to suggest that the AHAS encoded by ilvB1 and ilvH of M. tuberculosis is probably a hybrid of the type II and type III isozymes of enterobacteria. A search for genes encoding AHAS in another intracellular mycobacterial pathogen, Mycobacterium leprae, showed the presence of the following genes coding for large subunits of AHAS: ilvB, ilvG and ilvX (KEGG database). Since a large number of genes required for in vitro growth have been lost in this obligate human pathogen (Cole et al., 2001) , these findings suggest that multiple ilv genes might play a role in the survival of mycobacteria under in vivo conditions. IlvB1 is essential in the absence of BCAA
To decipher the roles of the multiple genes coding for large subunits of AHAS, we inactivated the ilvB1 gene of M. tuberculosis H37Rv by homologous recombination, following a two-step method described by Parish & Stoker (2000) . To ensure that no active IlvB protein was made, the portion of the ilvB gene downstream of the introduced deletion was rendered out of frame, which meant that the construct could only code for an 85 aa (out of 618 residues) truncated polypeptide. Since the mutation in the ilvB1 gene was an unmarked one, free from polar effects associated with antibiotic markers, the expression of the downstream genes of the operon (ilvN and ilvC) should not have been affected. Out of 16 colonies of SCO recombinants screened, 3 colonies had the plasmid integrated in the proper locus, as confirmed by PCR using primers 355 and 359 ( Supplementary Fig. S3a ). One of the SCO recombinants ( Supplementary Fig. S3b, lane 4) was grown in the absence of hygromycin for 3 weeks and subsequently plated either on 7H9 plates containing 2 % sucrose or on 7H9 plates containing 2 % sucrose and supplemented with ILV (each 100 mg ml 21 ) and pantothenic acid (50 mg ml 21 ). The colonies growing in the presence of sucrose were screened for loss of the plasmid by PCR amplification of the hyg r and sacB genes; 80 % of the colonies growing on sucrose plates were found to have lost the plasmid. No ilvB1 mutant colonies were obtained in the absence of BCAA in the medium, indicating that the ilvB1 gene is essential in the absence of BCAA and that the genes coding for putative large subunits of AHAS (ilvB2, ilvG and ilvX) were unable to complement the loss of ilvB1 under the conditions employed. Screening of colonies from ILVcontaining plates, by PCR using gene-specific primers, showed that 94 % of the colonies had retained the wildtype copy of the gene, while the remaining 6 % were found to harbour a deletion in the ilvB1 gene (data not shown).
The absence of the wild-type copy in one of the DCO mutants (no. 19) was further confirmed by PCR (Fig. 2b) , using primers corresponding to the regions indicated in Fig. 2(a) . Finally, Southern blot analysis, using a probe corresponding to the internal regions of the ilvB1 gene, showed the presence of an expected smaller fragment in the DilvB1/19 mutant (Fig. 2c) .
In order to understand the expression profile of IlvB1 under active-growth and stationary-phase conditions, the M. tuberculosis cell lysates were subjected to Western analysis using antibodies raised against the IlvB1 protein.
However, because multiple protein bands were detected, probably due to antibody cross-reactivity with the putative large subunits of AHAS (IlvB1, IlvB2, IlvG and IlvX), the results were inconclusive (data not shown). Further studies are required to understand the changes in expression of IlvB1 and other AHAS subunits under varied physiological conditions.
In vitro growth characteristics of M. tuberculosis DilvB1/19
Since 2-ketoisovalerate is a common intermediate for synthesis of BCAA and pantothenate, we analysed the nutritional requirements of M. tuberculosis DilvB1/19 for ILV and pantothenate. No growth was seen in the absence of ILV (Fig. 3a) . Addition of pantothenic acid stimulated growth, but the mutant cultures were found to grow in its absence also (data not shown). To ascertain whether the mutant was auxotrophic for all three amino acids, cultures were grown in the presence of IL, IV or LV. The DilvB1/19 mutant was found to be auxotrophic for all three BCAA, as no growth of this mutant was observed in the absence of any one of these amino acids from the medium (Fig. 3b ). The growth kinetics following addition of increasing concentrations of the amino acids indicated that the mutant strain required a minimum of 50 mg ml 21 each amino acid for growth. Growth was poor at 20 mg ml 21 and no growth was observed below 20 mg ml 21 (Fig. 3a) . Upon complementation with a copy of the ilvB1 gene in an integrating vector, the wild-type phenotype could be restored and the cultures could grow in the absence of the three amino acids, confirming that the inactivation of the ilvB1 gene leads to auxotrophic requirement for BCAA (data not shown). Since inactivation of individual ilv genes in enterobacteria leads to BCAA auxotrophy only when the bacteria are grown on glucose or a C 2 carbon source (Dailey et al., 1987) , we investigated whether M. tuberculosis DilvB1 was prototrophic when grown in the presence of a C 2 carbon source. For this purpose, the mutant culture was diluted 1 : 100 and inoculated into Dubos medium containing palmitate as a source of C 2 units. No growth could be seen in the absence of ILV, indicating the requirement of these amino acids for growth in a C 2 carbon source (data not shown).
In vitro survival kinetics of M. tuberculosis DilvB1/19
In order to determine whether ILV depletion leads to cessation of growth (static effect) or loss of viability (cidal effect) in M. tuberculosis in vitro, the viability of the mutant culture, maintained at different concentrations of ILV, was measured over a period of time. For this purpose, M. tuberculosis DilvB1/19 grown with ILV was washed and resuspended in 7H9 containing 0, 20 or 100 mg ILV ml 21 . Samples were taken at various time intervals and plated on 7H9 containing ILV (100 mg ml 21 ) and pantothenate (50 mg ml 21 ). As shown in Fig. 3(c) , there was a continuous drop in the number of c.f.u. of M. tuberculosis DilvB1/19 grown in the absence of ILV. The culture maintained in 20 mg ILV ml 21 also showed loss of viability, but the rate of death was slower than that of cultures with no ILV. The M. tuberculosis DilvB1/19 culture grown in the presence of 100 mg ILV ml 21 showed an increase in the number of c.f.u. (Fig. 3c ). This clearly proves that depletion of the intracellular pool of BCAA results in death of M. tuberculosis.
Growth of M. tuberculosis DilvB1/19 in macrophages
In order to assess the contribution of ilvB1 to survival in macrophages, an M. tuberculosis DilvB1/19 culture, washed free of amino acids, was used to infect BMDM at an m.o.i. of 10. Since the macrophages did not grow well in the complete absence of ILV, the survival of the mutant bacteria inside macrophages in the absence of BCAA could not be studied. Instead, the macrophages were maintained in the presence of 20 mg ILV ml 21 , which is close to the physiological concentration of BCAA in vivo in humans (Filho et al., 1997) . At this concentration of ILV, the macrophages proliferated well and were found to be healthy. The infected macrophages were lysed at regular intervals (1, 4, 7 and 11 days post-infection) and plated on 7H9 medium containing ILV (100 mg ml 21 ) and pantothenate (50 mg ml 21 ). The number of c.f.u. obtained from the ilvB1/19 mutant was similar to the bacterial counts obtained from the wild-type M. tuberculosis H37Rv on all days of sampling (Fig. 4) . The mutant cultures harvested from the macrophages did not grow in the absence of ILV, showing that they had not reverted to prototrophy (data not shown). Since a suboptimal concentration of ILV (20 mg ml 21 ) does not support the growth of the M. tuberculosis DilvB1/19 mutant culture in vitro, the macrophage survival kinetics suggested that intracellular survival of DilvB1/19 in the presence of a suboptimal concentration of ILV was due either to an accumulation of ILV inside macrophages by active uptake, or to other genes encoding the large subunit of AHAS being active in the intracellular environment.
M. tuberculosis DilvB1/19 is attenuated for growth in mice
In order to study the effect of ilvB1 inactivation on replication and survival of M. tuberculosis in mice, the mutant strain was used to infect mice intravenously and the growth of bacteria was monitored by quantification of bacterial loads in the lungs and spleen at regular intervals, for 4 weeks. All cultures were plated on 7H9 containing 100 mg ILV ml 21 . As shown in Fig. 5a , the initial bacterial loads of the three strains in the lungs and spleens varied slightly, with the mutant strain showing higher c.f.u. in both organs. Small differences in the initial bacterial loads in the organs of mice have been observed previously, and this is not expected to influence the outcome of infection (Ewann et al., 2002; Sun et al., 2004) . In contrast to the wild-type bacteria, which increased in numbers in the lungs of infected animals over a period of 4 weeks (from 1.3610 4 to 2.6610 5 c.f.u.), the ilvB1 mutant was found to be attenuated for growth in the lungs, since despite a higher bacterial load at the beginning of infection, it showed a slow reduction in c.f.u. over this period (from 1.8610 4 to 4.6610 2 c.f.u., Fig. 5a ). The M. tuberculosis mutant strain complemented with a copy of the ilvB gene behaved in a similar manner to the wild-type strain, and showed an increase in c.f.u. in the lungs of infected animals (from 1.0610 3 to 1.6610 5 c.f.u.). A similar picture was seen in the spleen, where the wild-type and the complemented strain showed an increase in the number of bacteria recovered, whereas the mutant strain showed a small decline in the number of c.f.u. recovered over a period of 4 weeks (Fig. 5b) . Even though the mutant was attenuated in virulence compared to the wild-type M. tuberculosis, it persisted in the organs of the infected mice and was not eliminated completely in four weeks. The bacteria obtained from organs of animals infected with M. tuberculosis DilvB1/19 were dependent on ILV for growth in vitro, ruling out the possibility of reversion to prototrophy under in vivo conditions.
DISCUSSION
Although described as IlvBN in earlier reports (Zohar et al., 2003; Choi et al., 2005) , which suggested similarity to type I AHAS of E. coli, our bioinformatics analysis predicts the major AHAS of M. tuberculosis to be a hybrid of the type II and type III E. coli AHAS. This view is supported by earlier Fig. 4 . Growth of the DilvB1/19 mutant in BMDM. The macrophages were infected with the wild-type and the mutant M. tuberculosis in triplicate. The infected macrophages were lysed at the indicated time intervals and plated on 7H10 in the presence of ILV (100 mg ml "1 ) and pantothenate (50 mg ml "1 ). The experiment was repeated twice and results from one experiment are shown (mean±SEM).
studies on AHAS of the Gram-positive bacterium B. stearothermophilus, in which ALS (encoded by ilvBN) was proposed to be similar to AHAS III of E . coli (Porat et al., 2004) . Biochemical characterization of IlvBN from M. tuberculosis and M. avium showed that the recombinant enzyme was sensitive to valine, and that the AHAS activity could be inhibited by sulfonylureas (Zohar et al., 2003; Choi et al., 2005) , thus making it a functional equivalent of the type II enzyme of enterobacteria. Although Grampositive bacteria possess a single species of AHAS, mostly classified as IlvBN type (Keilhauer et al., 1993; Porat et al., 2004) , the presence of multiple genes coding for the catalytic subunits of AHAS in M. tuberculosis points towards the possible existence of multiple AHAS isozymes in this organism.
The inability of the ilvB1 mutant to grow in the absence of ILV in the medium showed that none of the other AHAS catalytic subunits could compensate for the loss of IlvB1. This indicates either that these proteins are not expressed optimally under in vitro conditions, or that they exhibit insufficient activity to synthesize the required amounts of BCAA. The physiological role of the multiple large subunits of M. tuberculosis AHAS under other physiological states remains unclear. Since most of the genes present in the bacterial genome are active under the correct physiological condition (Tamburini & Mastromei, 2000) , it will be interesting to see under what growth conditions ilvB2, ilvG and ilvI are expressed. The lack of a growth defect shown by the ilvB1 mutant in macrophages in the presence of a suboptimal concentration of ILV could be due either to uptake of BCAA from the in vivo environment or to the mutants having the ability to synthesize some BCAA using an alternative mechanism, or to a combination of both.
Although the DilvB1 mutant is attenuated for replication in mice, it manages to persist in the organs of infected mice. The growth defects shown by amino acid auxotrophs of M. tuberculosis in animals suggest that sufficient amounts of amino acids are not available to M. tuberculosis in mice (Hondalus et al., 2000; Smith et al., 2001; Sambandamurthy & Jacobs, 2005) . This raises the possibility that the other AHAS enzymes, IlvB2, IlvG and IlvX, which do not seem to have any role in BCAA synthesis in vitro, might be able to provide some activity in vivo, thus enabling the bacteria to synthesize suboptimal levels of BCAA, allowing survival, but not providing enough BCAA for growth. Further studies on expression profiling, gene inactivation and in vitro biochemical characterization of IlvB2, IlvG and IlvX will help to resolve these issues. Earlier studies on gene inactivation in enterobacteria have demonstrated that the multiplicity of AHAS has evolved to help the organisms in adapting to growth on C 2 or C 6 carbon sources, in the absence of external supplies of amino acids (Barak et al., 1987; Dailey et al., 1987) . Since M. tuberculosis is known to utilize C 2 as the preferred carbon source for intracellular survival and replication (Muñoz-Elias & McKinney, 2006) , it can be speculated that some AHAS isozymes might be functional under similar alternative physiological conditions. In the absence of genes coding for multiple regulatory subunits (small subunit), it can be postulated either that these catalytic subunits do not require the regulatory subunits for activity, or that all of them can associate with the lone regulatory subunit, IlvH. Evidence for both of these possibilities emerges from the earlier studies on the activity shown by the isolated catalytic AHAS subunit of B. stearothermophilus and subsequent increase in activity upon reconstitution with an E. coli AHAS III regulatory subunit (Porat et al., 2004) . The retention of genes coding for multiple catalytic subunits of AHAS in M. leprae, an organism that has lost a Fig. 5 . Growth kinetics of wild-type M. tuberculosis H37Rv, the DilvB1/19 mutant and the complemented mutant in vivo in mice. (a) Lungs, (b) spleen. BALB/c mice were injected with the mycobacterial cultures and bacterial growth was monitored by quantification of the c.f.u. obtained by plating organ homogenates on 7H11 plates supplemented with ILV (100 mg ml "1 ) and pantothenate (50 mg ml "1 ). The data represent the mean±SEM c.f.u. of wild-type, DilvB1/19 mutant and complemented M. tuberculosis strains, obtained from the lungs or spleens of five animals at each time point.
Branched-chain amino acids (ILV) auxotrophy in Mtu large number of genes not required for growth in vitro (Cole et al., 2001) , also indicates that multiple AHAS might help in survival in vivo.
Although the rapid loss of viability observed with the ilvB1 mutant in a medium lacking ILV suggested that inhibition of IlvB1 alone would lead to killing of M. tuberculosis under in vitro growth conditions, persistence of the ilvB1 mutant in mice indicates that IlvB1 inhibition alone would not lead to rapid killing of M. tuberculosis in vivo. The in vivo and ex vivo growth inhibition of M. tuberculosis by sulfometuron methyl and its derivatives, shown in earlier studies (Grandoni et al., 1998; Sohn et al., 2008) , may possibly have resulted from inhibition of all of the in vivo-active isozymes of AHAS. In vitro inhibition studies with other AHAS isozymes of M. tuberculosis will provide the necessary evidence for this contention.
Studies of a number of BCAA auxotrophic mutants of intracellular pathogens, such as S. typhimurium, B. pseudomallei and Listeria monocytogenes, have shown that due to limited availability of these amino acids in vivo, the mutant bacteria are attenuated in virulence, and thus have been proposed as vaccine candidates (Hoiseth & Stocker, 1981; Alexander et al., 1993; Atkins et al., 2002) . This has been found to be true for M. tuberculosis as well, where it has been observed that mutants requiring purines, leucine, pantothenate or arginine were defective for growth in macrophages and mice, and these have proven to be good vaccine candidates, as shown by their efficacy in animals, which has been comparable to the current BCG vaccine (Jackson et al., 1999; Hondalus et al., 2000; Smith et al., 2001; Sambandamurthy & Jacobs, 2005) . As the ilvB1 mutant is sufficiently attenuated and can persist in mice for long periods, there is a possibility of using this mutant as a vaccine candidate.
